Home » Topics » BioWorld Science, Cardiovascular

BioWorld Science, Cardiovascular
RSS

ITMR system phase II trial expansion granted

June 14, 1996

Selective PDGF inhibitors revealed

June 14, 1996

More Na+/H+-exchange inhibitors from E. Merck

June 14, 1996

Na+/H+-exchange inhibitors from Sumitomo

June 14, 1996

Cardiovascular disorders treatment from Boryung Pharm.

June 14, 1996

Merck & Co. discloses endothelin antagonists

June 14, 1996

Endothelin antagonists from Abbott

June 14, 1996

Tranilast: An angiotensin II antagonist

June 7, 1996

Cytel's cell adhesion inhibitor trial discontinued

June 7, 1996

First chronotherapeutic agent for hypertension and angina now avaliable in U.S.

June 7, 1996

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...